158 related articles for article (PubMed ID: 36925025)
1. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.
Zhao Y; Zheng Y; Zhu Y; Ding K; Zhou M; Liu T
Int J Pharm; 2023 Apr; 636():122844. PubMed ID: 36925025
[TBL] [Abstract][Full Text] [Related]
2. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer.
Zhao Y; Zheng Y; Zhu Y; Zhang Y; Zhu H; Liu T
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575569
[TBL] [Abstract][Full Text] [Related]
3. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
4. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
6. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.
Yu X; Di Y; Xie C; Song Y; He H; Li H; Pu X; Lu W; Fu D; Jin C
Int J Nanomedicine; 2015; 10():6825-34. PubMed ID: 26586944
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer.
Dora CP; Kushwah V; Yadav V; Kuche K; Jain S
Mol Pharm; 2024 Jun; 21(6):2699-2712. PubMed ID: 38747900
[TBL] [Abstract][Full Text] [Related]
8. Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
Kushwah V; Agrawal AK; Dora CP; Mallinson D; Lamprou DA; Gupta RC; Jain S
Pharm Res; 2017 Nov; 34(11):2295-2311. PubMed ID: 28795274
[TBL] [Abstract][Full Text] [Related]
9. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
11. A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy.
Ma T; Jiang JL; Qi WX; Chen JY; Xu HP
Drug Des Devel Ther; 2022; 16():2395-2406. PubMed ID: 35923931
[TBL] [Abstract][Full Text] [Related]
12. High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as an Image-Guided Tumor-Selective Drug-Delivery System to Treat Pancreatic Cancer.
Ischyropoulou M; Sabljo K; Schneider L; Niemeyer CM; Napp J; Feldmann C; Alves F
Adv Mater; 2023 Nov; 35(46):e2305151. PubMed ID: 37587542
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
[TBL] [Abstract][Full Text] [Related]
14. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
15. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
19. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer.
Ray P; Ferraro M; Haag R; Quadir M
Macromol Biosci; 2019 Jul; 19(7):e1900073. PubMed ID: 31183964
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]